Literature DB >> 15720237

Amyloidosis and auto-inflammatory syndromes.

Gilles Grateau1, Isabelle Jéru, Saad Rouaghe, Cécile Cazeneuve, Nathalie Ravet, Philippe Duquesnoy, Laurence Cuisset, Catherine Dodé, Marc Delpech, Serge Amselem.   

Abstract

Amyloidosis remains currently a severe potential complication of many chronic inflammatory disorders. It is not exactly know why some patients develop a progressive amyloidosis, whereas others do not although latent deposits may be present. A permanent acute phase response, ideally evaluated with serial measurement of serum protein SAA, the precursor of the AA protein deposited in tissues, seems to be a prerequisite to the development of inflammatory (AA) amyloidosis. Genetic factors have however been recently emphasized. Among persistent or emerging causes of AA amyloidosis, hereditary periodic fever syndromes also known as auto-inflammatory syndromes are a group of diseases characterised by intermittent bouts of clinical inflammation with focal organ involvement mainly: abdomen, musculoskeletal system and skin. The most frequent is familial Mediterranean fever which affects patients of Mediterranean descent all over the world. Three other types have been recently clinically as well as genetically characterised. A thorough diagnosis is warranted, as clinical and therapeutic management is specific for each of these diseases.

Entities:  

Mesh:

Year:  2005        PMID: 15720237     DOI: 10.2174/1568010053622786

Source DB:  PubMed          Journal:  Curr Drug Targets Inflamm Allergy        ISSN: 1568-010X


  2 in total

Review 1.  Genetics of monogenic autoinflammatory diseases: past successes, future challenges.

Authors:  Ivona Aksentijevich; Daniel L Kastner
Journal:  Nat Rev Rheumatol       Date:  2011-07-05       Impact factor: 20.543

2.  Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment.

Authors:  H Morbach; P Richl; S Stojanov; P Lohse; Hermann J Girschick
Journal:  Rheumatol Int       Date:  2009-12       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.